Global Pharma Giants Announce Major Expansions Creating Thousands of New Jobs in Pharma Across the U.S. and Europe

Leading pharmaceutical companies including AbbVie, Amgen, Eli Lilly, Biocon, and Gilead are investing billions in new manufacturing facilities, generating thousands of high-paying new jobs in pharma, biotech, and life sciences across the United States and Europe.

BioSpectrum Jobs, the leading platform for healthcare and life sciences careers, reports a surge in new job opportunities as global pharmaceutical companies announce landmark investments in advanced manufacturing facilities worldwide. These developments highlight strong growth in the biopharma sector and the creation of thousands of new jobs in pharma, research, and technology.

Key Pharma Expansions Creating Jobs:

• AbbVie – North Cicago, Illinois
• New API manufacturing facility under construction.
• Supports domestic production of neuroscience, immunology, and oncology medicines.
• Expected to create hundreds of new pharma manufacturing and technical roles.
• “AbbVie’s investment strengthens U.S. manufacturing and delivers new career opportunities,” said Azita Saleki-Gerhardt, Executive VP & COO, AbbVie.
• Amgen – Juncos, Puerto Rico
• $650 million expansion of biologics manufacturing network.
• Creates 750 new construction and highly skilled manufacturing jobs.
• “This facility opens doors to high-skilled pharma careers and strengthens supply chain resilience,” said Robert A. Bradway, CEO, Amgen.
• Mölnlycke Health Care – Brunswick, Maine
• $135 million wound care manufacturing expansion.
• Workforce to grow by 10%, offering new roles for technicians, engineers, and production staff.
• Sustainability-focused facility using renewable energy.
• Eli Lilly – Goochland County, Virginia
• $5 billion next-generation API and bioconjugate facility.
• Expected to create 650 skilled jobs and 1,800 construction jobs.
• Supports domestic production of monoclonal antibodies and antibody-drug conjugates.
• Biocon – Cranbury, New Jersey
• First U.S. FDA-approved formulations facility.
• Creates new opportunities in R&D, manufacturing, and quality assurance.
• Enhances access to therapies across the U.S.
• Gilead Sciences – Foster City, California
• Pharmaceutical Development and Manufacturing Technical Development Center (NTDC).
• Over 3,000 new jobs expected in biotech manufacturing, research, and operations.
• Focus on biologics, oncology, virology, and inflammation therapies.
• Merck – Cork, Ireland
• €150 million climate-neutral filtration plant.
• Adds 200 new jobs in pharmaceutical manufacturing.
• Delpharm – Boucherville, Quebec
• $220 million modernization project.
• Preserves 500 specialized pharma jobs, expanding sterile drug production.
• Quasar Medical – Ireland & Mexico
• Acquisition of Nordson units creates 200 new development and manufacturing roles.
• Enzene – New Jersey
• New biomanufacturing hub generates hundreds of new jobs in biotech production, R&D, and operations.

These expansions collectively represent over 10,000 new roles globally, underscoring the industry’s resilience, innovation, and long-term growth potential.

As companies invest billions in next-generation manufacturing, they’re not only advancing science but also empowering professionals across the industry to shape the future of healthcare.

Read Detailed Press Releases Here